Application of conditionally replicating herpes vector for gene therapy treatment of urologic neoplasms

M. Oyama, K. Uyemura, M. Murai, T. Yazaki, T. Ohigashi, M. Hoshi, Y. Horiguchi, Mototsugu Oya, H. Asakura, J. Nakashima, M. Tachibana

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Herpes vector has been widely used for experimental gene therapy. We herein review the strategies of such therapy for the treatment of urologic neoplasms. Most experimental studies of genetically altered viruses have employed replication-incompetent vectors. However, such viruses are unable to infect additional cells subsequent to the initial infection event. Therefore, this strategy has relied heavily on the bystander effect because a large number of noninfected tumor cells remain. Conditionally replicating herpes vector G207 has been developed in order to overcome potential problems of safety and tumor specificity for human use. It has been used to treat malignant brain tumors because of its neural tropism. In the last few years, applications of G207 for non-neural tumors have been reported. Because G207 may be useful for the treatment of urologic malignant tumors, we evaluated the antitumor effect against several types of tumor cells both in vitro and in vivo. Our data suggest that G207 may be applicable for the treatment of urologic malignant tumors.

Original languageEnglish
Pages (from-to)83-87
Number of pages5
JournalMolecular Urology
Volume4
Issue number2
Publication statusPublished - 2000

Fingerprint

Urologic Neoplasms
Genetic Therapy
Neoplasms
Therapeutics
Bystander Effect
Viruses
Investigational Therapies
Tropism
Brain Neoplasms
Safety
Infection

ASJC Scopus subject areas

  • Urology

Cite this

Oyama, M., Uyemura, K., Murai, M., Yazaki, T., Ohigashi, T., Hoshi, M., ... Tachibana, M. (2000). Application of conditionally replicating herpes vector for gene therapy treatment of urologic neoplasms. Molecular Urology, 4(2), 83-87.

Application of conditionally replicating herpes vector for gene therapy treatment of urologic neoplasms. / Oyama, M.; Uyemura, K.; Murai, M.; Yazaki, T.; Ohigashi, T.; Hoshi, M.; Horiguchi, Y.; Oya, Mototsugu; Asakura, H.; Nakashima, J.; Tachibana, M.

In: Molecular Urology, Vol. 4, No. 2, 2000, p. 83-87.

Research output: Contribution to journalArticle

Oyama, M, Uyemura, K, Murai, M, Yazaki, T, Ohigashi, T, Hoshi, M, Horiguchi, Y, Oya, M, Asakura, H, Nakashima, J & Tachibana, M 2000, 'Application of conditionally replicating herpes vector for gene therapy treatment of urologic neoplasms', Molecular Urology, vol. 4, no. 2, pp. 83-87.
Oyama M, Uyemura K, Murai M, Yazaki T, Ohigashi T, Hoshi M et al. Application of conditionally replicating herpes vector for gene therapy treatment of urologic neoplasms. Molecular Urology. 2000;4(2):83-87.
Oyama, M. ; Uyemura, K. ; Murai, M. ; Yazaki, T. ; Ohigashi, T. ; Hoshi, M. ; Horiguchi, Y. ; Oya, Mototsugu ; Asakura, H. ; Nakashima, J. ; Tachibana, M. / Application of conditionally replicating herpes vector for gene therapy treatment of urologic neoplasms. In: Molecular Urology. 2000 ; Vol. 4, No. 2. pp. 83-87.
@article{be45116f3afb4cc6aae6be159af6226c,
title = "Application of conditionally replicating herpes vector for gene therapy treatment of urologic neoplasms",
abstract = "Herpes vector has been widely used for experimental gene therapy. We herein review the strategies of such therapy for the treatment of urologic neoplasms. Most experimental studies of genetically altered viruses have employed replication-incompetent vectors. However, such viruses are unable to infect additional cells subsequent to the initial infection event. Therefore, this strategy has relied heavily on the bystander effect because a large number of noninfected tumor cells remain. Conditionally replicating herpes vector G207 has been developed in order to overcome potential problems of safety and tumor specificity for human use. It has been used to treat malignant brain tumors because of its neural tropism. In the last few years, applications of G207 for non-neural tumors have been reported. Because G207 may be useful for the treatment of urologic malignant tumors, we evaluated the antitumor effect against several types of tumor cells both in vitro and in vivo. Our data suggest that G207 may be applicable for the treatment of urologic malignant tumors.",
author = "M. Oyama and K. Uyemura and M. Murai and T. Yazaki and T. Ohigashi and M. Hoshi and Y. Horiguchi and Mototsugu Oya and H. Asakura and J. Nakashima and M. Tachibana",
year = "2000",
language = "English",
volume = "4",
pages = "83--87",
journal = "Molecular Urology",
issn = "1091-5362",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Application of conditionally replicating herpes vector for gene therapy treatment of urologic neoplasms

AU - Oyama, M.

AU - Uyemura, K.

AU - Murai, M.

AU - Yazaki, T.

AU - Ohigashi, T.

AU - Hoshi, M.

AU - Horiguchi, Y.

AU - Oya, Mototsugu

AU - Asakura, H.

AU - Nakashima, J.

AU - Tachibana, M.

PY - 2000

Y1 - 2000

N2 - Herpes vector has been widely used for experimental gene therapy. We herein review the strategies of such therapy for the treatment of urologic neoplasms. Most experimental studies of genetically altered viruses have employed replication-incompetent vectors. However, such viruses are unable to infect additional cells subsequent to the initial infection event. Therefore, this strategy has relied heavily on the bystander effect because a large number of noninfected tumor cells remain. Conditionally replicating herpes vector G207 has been developed in order to overcome potential problems of safety and tumor specificity for human use. It has been used to treat malignant brain tumors because of its neural tropism. In the last few years, applications of G207 for non-neural tumors have been reported. Because G207 may be useful for the treatment of urologic malignant tumors, we evaluated the antitumor effect against several types of tumor cells both in vitro and in vivo. Our data suggest that G207 may be applicable for the treatment of urologic malignant tumors.

AB - Herpes vector has been widely used for experimental gene therapy. We herein review the strategies of such therapy for the treatment of urologic neoplasms. Most experimental studies of genetically altered viruses have employed replication-incompetent vectors. However, such viruses are unable to infect additional cells subsequent to the initial infection event. Therefore, this strategy has relied heavily on the bystander effect because a large number of noninfected tumor cells remain. Conditionally replicating herpes vector G207 has been developed in order to overcome potential problems of safety and tumor specificity for human use. It has been used to treat malignant brain tumors because of its neural tropism. In the last few years, applications of G207 for non-neural tumors have been reported. Because G207 may be useful for the treatment of urologic malignant tumors, we evaluated the antitumor effect against several types of tumor cells both in vitro and in vivo. Our data suggest that G207 may be applicable for the treatment of urologic malignant tumors.

UR - http://www.scopus.com/inward/record.url?scp=0034131451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034131451&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 83

EP - 87

JO - Molecular Urology

JF - Molecular Urology

SN - 1091-5362

IS - 2

ER -